Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells 7,179 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 7,179 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $52,550.28. Following the sale, the chief financial officer now owns 291,486 shares of the company’s stock, valued at approximately $2,133,677.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Austin Aerts also recently made the following trade(s):

• On Tuesday, September 10th, Austin Aerts sold 5,056 shares of Sera Prognostics stock. The stock was sold at an average price of $7.57, for a total value of $38,273.92.

Sera Prognostics Price Performance

Shares of NASDAQ SERA traded down $0.20 during trading hours on Tuesday, reaching $7.24. The stock had a trading volume of 79,534 shares, compared to its average volume of 175,932. The business’s fifty day moving average is $7.41 and its two-hundred day moving average is $7.68. The company has a market cap of $241.59 million, a price-to-earnings ratio of -7.31 and a beta of 1.04. Sera Prognostics, Inc. has a twelve month low of $1.65 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the prior year, the business posted ($0.23) EPS. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

Several institutional investors have recently added to or reduced their stakes in SERA. American Century Companies Inc. lifted its position in shares of Sera Prognostics by 12.7% during the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after buying an additional 2,891 shares during the last quarter. Quest Partners LLC lifted its position in shares of Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Sera Prognostics during the 3rd quarter worth $78,000. The Manufacturers Life Insurance Company bought a new stake in shares of Sera Prognostics during the 2nd quarter worth $68,000. Finally, Prime Capital Investment Advisors LLC bought a new stake in shares of Sera Prognostics during the 3rd quarter worth $104,000. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.